 I think the latter is particularly focused given the propensity of shortages in generic sterile injectables, focused on the health system space where they're predominantly administered. And so there's a conversation there about how those programs, what those programs could look like, what would HHS need to do, what would FDA, CMS need to do, as well as what the private sector would need to do.